CN103463185A - Matched artemisia apiacea and agastache rugosaus combination medicine, preparation method and application thereof - Google Patents
Matched artemisia apiacea and agastache rugosaus combination medicine, preparation method and application thereof Download PDFInfo
- Publication number
- CN103463185A CN103463185A CN2013104513929A CN201310451392A CN103463185A CN 103463185 A CN103463185 A CN 103463185A CN 2013104513929 A CN2013104513929 A CN 2013104513929A CN 201310451392 A CN201310451392 A CN 201310451392A CN 103463185 A CN103463185 A CN 103463185A
- Authority
- CN
- China
- Prior art keywords
- medicine
- composition
- suddenly
- extract
- volatile oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
一种青霍药对组合药物、制备方法及其应用。本发明提供了一种以鲜活大青叶为原料制备靛玉红的方法,其特征在于:在粉碎鲜活大青叶菘蓝原料中添加吲哚醌;本发明体利用吲哚酚自由基的生成由原浸泡液中的溶解氧供氧即可,因此,通过体系pH的控制与酶解时控氧使反应向靛玉红方向发展;方法简便,可控;本发明直接利用大青叶的原料作为反应原料,有效的降低了生产成本;本发明在但是进吲哚酚自由基一步氧化生成时进行了控制,避免生成吲哚醌,而是直接在反应原料中添加吲哚醌,是反应向正向平衡。A combination drug of cyanosides, a preparation method and applications thereof. The invention provides a method for preparing indirubin by using fresh and alive Folium Isatis as raw material, which is characterized in that: adding indolequinone to the crushed fresh and alive Folium Isatis indica raw material; the present invention utilizes indoxyl free radicals The generation of the indirubin can be supplied by the dissolved oxygen in the original soaking liquid. Therefore, the reaction develops towards indirubin through the control of system pH and oxygen control during enzymatic hydrolysis; the method is simple and controllable; the present invention directly utilizes Folium folium The raw material is used as the reaction raw material, which effectively reduces the production cost; the present invention controls the generation of indoxyl free radicals during one-step oxidation, avoids the generation of indoloquinone, but directly adds indole quinone to the reaction raw material, is The response is toward positive equilibrium.
Description
技术领域technical field
本发明涉及一种中药材药对组合,更具体的说一种青霍药对组合药物、制备方法及其应用。The invention relates to a combination of traditional Chinese medicinal materials and medicines, more specifically, a combination medicine of qinghuo medicines, a preparation method and an application thereof.
背景技术Background technique
青蒿为菊科蒿属一年生草本植物,具清热解暑,除蒸截疟的功效,挥发油为其主要有效部位之一,具有抗菌消炎、解热止咳、平喘等药理作用。藿香为唇形科一年生或多年生草本植物,其主要成分含藿香挥发油,有抑菌防腐作用,对浅表层皮肤真菌感染也有治疗作用。据报道,青蒿与藿香配伍临床应用可以增强清热解暑和抗疟功效。Artemisia annua is an annual herb of the genus Artemisia in the family Asteraceae. It has the effects of clearing away heat and relieving heat, and eliminating steam and intercepting malaria. The volatile oil is one of its main effective parts. Huoxiang is an annual or perennial herb of Lamiaceae. Its main component contains volatile oil of Huoxiang, which has antibacterial and antiseptic effects, and also has a therapeutic effect on superficial skin fungal infections. According to reports, the clinical application of Artemisia annua and Huoxiang can enhance the efficacy of clearing heat, relieving summer heat and antimalarial.
青蒿中的药用成分可分为挥发性和非挥发性2个部分,非挥发性成分主要是青蒿素,它是一种含有过氧基团的倍半萜内酯,与已知抗疟药化学结构完全不同;其多种衍生物如双氢青蒿素、青蒿琥酯、蒿甲醚、蒿乙醚,均是治疗疟疾的有效单体。随着对青蒿素类药物药理作用研究的不断深入,已证实其具有抗疟、抗孕、抗纤维化、抗血吸虫、抗弓形虫、抗心律失常和肿瘤细胞毒性等作用;虽然该类药物作用广泛,但其作用机制、特点和应用仍处于初级阶段。挥发性成分主要为挥发油,包括篙酮、异篙酮、按油精、左旋樟脑、丁香烯、旅烯、龙脑、石竹烯氧化物、倍半褚醇等成分;其中樟脑、龙脑、丁香烯、篙酮、异篙酮等含量较高;挥发油具有解热镇痛、抗菌消炎、止咳平喘等功效。藿香的挥发性成分主要是甲基胡椒酚,占80%以上。并含茴香醚、茴香醛、d-柠檬烯、对-甲氧基桂皮醛、α-蒎烯、β-蒎烯、3-辛酮、3-辛醇、对-聚伞花烯等。藿香还包括槐黄素、椴素、蒙花苷、藿香苷、异藿香苷、藿香素。此外,尚含少量鞣质、苦味质等成分。The medicinal ingredients in Artemisia annua can be divided into two parts: volatile and non-volatile. The non-volatile component is mainly artemisinin, which is a sesquiterpene lactone containing a peroxy group, which is compatible with known antibacterial agents. The chemical structure of malaria drugs is completely different; its various derivatives such as dihydroartemisinin, artesunate, artemether, and artether are all effective monomers for the treatment of malaria. With the in-depth study on the pharmacological effects of artemisinin drugs, it has been confirmed that they have anti-malarial, anti-pregnancy, anti-fibrosis, anti-schistosomiasis, anti-toxoplasma gondii, anti-arrhythmia and tumor cytotoxic effects; although these drugs It has a wide range of functions, but its mechanism of action, characteristics and application are still in its infancy. The volatile components are mainly volatile oils, including ketone, isone, olein, L-camphor, caryophyllene, brigene, borneol, caryophyllene oxide, sesqui-alcohol and other components; among them, camphor, borneol, clove The content of alkenes, ketones, isone ketones, etc. is high; the volatile oil has antipyretic and analgesic, antibacterial and anti-inflammatory effects, cough and asthma and other effects. The volatile components of Huoxiang are mainly methyl piperonol, accounting for more than 80%. It also contains anisole, anisaldehyde, d-limonene, p-methoxycinnamaldehyde, α-pinene, β-pinene, 3-octanone, 3-octanol, p-cymene, etc. Ageratum also includes sophorin, lindenin, mongoside, ageoin, isoagein, and ageoin. In addition, it still contains a small amount of tannin, bitter quality and other ingredients.
对于青蒿和藿香的组合物的研究,熊运海等采用实验分析与气相色谱.质谱(GC-MS)法,分别测定藿香、青蒿挥发油及其复合物的抑菌圈直径与挥发油成分,并利用化学计量学解析法对重叠的色谱峰进行解析,得到各组分的纯色谱曲线和质谱,再通过质谱库对解析的纯组分进行定性,用总体积积分法进行定量。结果表明,藿香与青蒿挥发油复合后综合抑菌能力增强,产生了新的活性化合物。藿香与青蒿挥发油复合物在质与量上与单味药相比均发生显著变化。复合物主要化学组分基本为两个单味药物的加和,单味药物组分的相对含量都发生了变化,其中藿香组分在复合物中的相对含量较高。For the study of the composition of Artemisia annua and Artemisia annua, Xiong Yunhai et al. used experimental analysis and gas chromatography-mass spectrometry (GC-MS) to measure the diameter of the inhibition zone and the volatile oil components of the volatile oils of Artemisia annua and Artemisia annua and their compounds, respectively. The overlapping chromatographic peaks were analyzed by chemometric analysis method, and the pure chromatographic curves and mass spectra of each component were obtained, and then the analyzed pure components were qualitatively analyzed through the mass spectrum library, and quantified by the total volume integral method. The results showed that the comprehensive antibacterial ability of Huoxiang and Artemisia annua volatile oil was enhanced, and new active compounds were produced. The quality and quantity of the volatile oil compound of Huoxiang and Artemisia annua have significant changes compared with the single herb. The main chemical components of the complex are basically the sum of two single drugs, and the relative content of the single drug components has changed, among which the relative content of Huoxiang component in the compound is relatively high.
发明内容Contents of the invention
为解决上述问题,本发明在考察青蒿、藿香良种药材的不同提取部位、不同提取方法,及上述方法取得的浸膏的药理活性的基础上,提供了一种藿香和青蒿的药对提取物组合。In order to solve the above-mentioned problems, the present invention provides a medicinal product of Artemisia annua and Artemisia annua on the basis of investigating different extraction parts and different extraction methods of the improved medicinal materials of Artemisia annua and Artemisia annua, and on the basis of the pharmacological activity of the extract obtained by the above method. Combination of extracts.
一种青霍药对组合药物的制备方法,所述方法为将青蒿和藿香两种药材混合提取,得到挥发油部位成分和乙醇提取部位成分,混合挥发油部位成分和乙醇提取部位成分得到青霍药对组合药物。A method for preparing a combination medicine of Qinghuo medicine. The method is to mix and extract two kinds of medicinal materials, Artemisia annua and Huoxiang, to obtain the components of the volatile oil part and the components of the ethanol extraction part, and mix the components of the volatile oil part and the components of the ethanol extraction part to obtain Qinghuo Drugs versus Combination Drugs.
所述方法包括如下步骤:The method comprises the steps of:
1)将青蒿、藿香两种药材等比例混合,根据《药典》(2010)方法提取挥发油部位;1) Mix the two medicinal materials of Artemisia annua and Huoxiang in equal proportions, and extract the volatile oil parts according to the method of "Pharmacopia" (2010);
2)将步骤1)中的残渣,用70%的乙醇回流提取,合并回收乙醇提取液;2) Extract the residue in step 1) with 70% ethanol under reflux, and combine and recover the ethanol extract;
3)回收乙醇提取液中的乙醇,收膏至25℃密度1.3,得到乙醇提取部位;3) Recover the ethanol in the ethanol extract, collect the paste to a density of 1.3 at 25°C, and obtain the ethanol extraction site;
4)合并挥发油部位和乙醇提取部位,得到青霍药对组合药物。4) Combining the volatile oil part and the ethanol extraction part to obtain the combination drug of qinghuo medicine.
3.根据权利要求2所述的青霍药对组合药物的制备方法,其特征在于:所述青蒿和藿香药材为采收后24内的鲜品,提取前的保藏温度低于25℃。3. The preparation method of Qinghuo medicine combination medicine according to claim 2, characterized in that: said Artemisia annua and Huoxiang medicinal materials are fresh products within 24 hours after harvesting, and the storage temperature before extraction is lower than 25°C .
一种青霍药对组合药物,所述青霍药对组合药物为采用权利要求1-3所述的方法的制备得到青霍药对组合药物。A combination medicine of Cincinnia cholera, which is prepared by adopting the method described in claims 1-3.
上述所述的青霍药对组合药物在制备治疗湿疹药物中的应用。The application of the combination of the above-mentioned green cholera medicines in the preparation of medicines for treating eczema.
上述所述的青霍药对组合药物在制备止咳化痰药物中的应用。Application of the combination of the above-mentioned green cholera medicines in the preparation of medicines for relieving cough and reducing phlegm.
本发明的有益技术效果是:本发明提供的青霍药对组合药物利用了混合药材的提取的过程中发生的化学反应,起到药对的有益技术效果,相比较两种药材的的挥发油单体,以及两种药物提取的组合;青霍药对组合药物作为外用药治疗湿疹和作为内用药物止咳化痰发面的活性均具有明显的优势;具体为:The beneficial technical effects of the present invention are: the combination drug of cyanosides provided by the invention utilizes the chemical reaction that occurs in the extraction process of the mixed medicinal materials, and plays the beneficial technical effect of the medicinal pair. body, and the combination of the two kinds of drug extraction; Qinghuo medicine has obvious advantages to the combined drug as an external drug for treating eczema and as an internal drug for cough and phlegm; specifically:
1)与青蒿和藿香分别单独提取的提物组合相比,在治疗湿疹方面具有显著进步;1) Compared with the combination of extracts extracted separately from Artemisia annua and Huoxiang separately, it has a significant improvement in the treatment of eczema;
2)在与青蒿和藿香挥发油及其混合物相比,在止咳和化痰方面具有显著进步;2) Compared with the volatile oil of Artemisia annua and Huoxiang and their mixtures, it has significant progress in relieving cough and reducing phlegm;
3)采用藿香和青蒿的鲜品提取挥发油和醇提物的组合在治疗湿疹和止咳化痰方面的活性更好。3) The combination of volatile oil and alcohol extracts extracted from fresh products of Huoxiang and Artemisia annua has better activity in treating eczema and relieving cough and reducing phlegm.
具体实施方式Detailed ways
实施例1青霍提取物的制备The preparation of embodiment 1 Qinghuo extract
分别对藿香、黄蒿花干品原料粉碎,过40目筛后各称取200g,按《中华人民共和国药典》(2010版)挥发油提取法分别提取藿香挥发油和青蒿挥发油;分别将上述两份药材残渣挥干水分,用药材重量5倍70%乙醇回流提取3次,分别合并提取液,收干,制备浸膏,得到藿香挥醇提取物和青蒿醇提取物。按藿香和黄蒿花1:1的比例称取一定量的藿香挥醇提取物、青蒿醇提取物、藿香挥发油和青蒿挥发油混合得到青藿提取物混合组I;将上述藿香挥发油和青蒿挥发油按原药材1:1的比例混合,得到青藿挥发油混合组A。Respectively pulverize the dry product raw materials of Huoxiang and Artemisia annua, respectively weigh 200g after crossing a 40-mesh sieve, and extract Huoxiang volatile oil and Artemisia annua volatile oil respectively by the volatile oil extraction method of "The Pharmacopoeia of the People's Republic of China" (2010 edition); The residues of the two medicinal materials were evaporated to dryness, refluxed and extracted with 70% ethanol 5 times the weight of the medicinal materials for 3 times, the extracts were combined respectively, dried, and the extract was prepared to obtain the alcohol extract of Huoxiang and artemisinin. Weigh a certain amount of Huoxiang volatile alcohol extract, Artemisia annua alcohol extract, Huoxiang volatile oil and Artemisia annua volatile oil according to the ratio of 1:1 of Huoxiang and Artemisia annua to obtain the mixed group I of Qinghuo extract; The volatile oil of fenugreek and the volatile oil of Artemisia annua were mixed according to the ratio of 1:1 of the original medicinal materials to obtain the mixed group A of volatile oil of Qinghuo.
分别对藿香、黄蒿花干品原料粉碎,过40目筛后各称取200g,按《中华人民共和国药典》(2010版)挥发油提取法分别提取藿香挥发油和青蒿挥发油;分别将上述两份药材残渣挥干水分,用药材重量5倍70%乙醇回流提取3次,分别合并提取液,收干,制备浸膏,得到藿香挥醇提取物和青蒿醇提取物。按藿香、黄蒿花1:1的比例称取一定量的藿香挥醇提取物、青蒿醇提取物、藿香挥发油和青蒿挥发油混合得到青藿提取物混合组II;将上述藿香挥发油和青蒿挥发油按原药材1:1的比例混合,得到青藿挥发油混合组B。Respectively pulverize the dry product raw materials of Huoxiang and Artemisia annua, respectively weigh 200g after crossing a 40-mesh sieve, and extract Huoxiang volatile oil and Artemisia annua volatile oil respectively by the volatile oil extraction method of "The Pharmacopoeia of the People's Republic of China" (2010 edition); The residues of the two medicinal materials were evaporated to dryness, refluxed and extracted with 70% ethanol 5 times the weight of the medicinal materials for 3 times, the extracts were combined respectively, dried, and the extract was prepared to obtain the alcohol extract of Huoxiang and artemisinin. Weigh a certain amount of Huoxiang volatile alcohol extract, Artemisia annua alcohol extract, Huoxiang volatile oil and Artemisia annua volatile oil according to the ratio of 1:1 of Huoxiang and Artemisia annua to obtain the mixed group II of Qinghuo extract; The volatile oil of fenugreek and the volatile oil of Artemisia annua were mixed according to the ratio of 1:1 of the original medicinal materials to obtain the mixed group B of volatile oil of Qinghuo.
分别对藿香、黄蒿花干品原料粉碎,过40目筛后各称取200g,混合,按《中华人民共和国药典》(2010版)挥发油提取法分别提取藿香和青蒿挥发油的混合物;得到药对青藿挥发油混合组C;将提取的药材残渣挥干水分,用药材重量5倍70%乙醇回流提取3次,合并提取液,收干,制备浸膏,得到得到药对青藿提取物混合组III。Grind the dry raw materials of Huoxiang and Artemisia annua respectively, weigh 200g after passing through a 40-mesh sieve, mix, and extract the mixture of Huoxiang and Artemisia annua volatile oil respectively according to the volatile oil extraction method of "Pharmacopia of the People's Republic of China" (2010 edition); The mixed group C of the volatile oil of Qinghuo Herba is obtained; the residue of the extracted medicinal materials is evaporated to dryness, and the weight of the medicinal materials is 5 times the weight of 70% ethanol for reflux extraction for 3 times, the extracts are combined, dried, and the extract is prepared to obtain the extract of Qinghuo Herba. Mixture Group III.
分别对藿香、黄蒿花鲜品(采收24h内)原料粉碎,各称取200g,混合,按《中华人民共和国药典》(2010版)挥发油提取法分别提取藿香和青蒿挥发油的混合物;得到药对青藿挥发油混合组D;将提取的药材残渣挥干水分,用药材重量5倍70%乙醇回流提取3次,合并提取液,收干,制备浸膏,得到得到药对青藿提取物混合组IV。Grind the raw materials of Huoxiang and Artemisia annua fresh products (within 24 hours of harvesting), weigh 200g each, mix, and extract the mixture of Huoxiang and Artemisia annua volatile oils respectively according to the volatile oil extraction method of "Pharmacopia of the People's Republic of China" (2010 edition) ; Obtain the mixed group D of the volatile oil of Herba Pleurotus chinensis; evaporate the water of the extracted medicinal material residue, and extract 5 times of 70% ethanol reflux with the weight of the material for 3 times, combine the extracts, dry up, prepare the extract, and obtain the medicinal material Extract Mix Group IV.
分别对藿香、黄蒿花鲜品(采收24h内)原料粉碎,各称取200g,混合,用药材重量5倍70%乙醇回流提取3次,合并提取液,收干,制备浸膏,得到得到药对青藿提取物混合组V。Grind the raw materials of Huoxiang and Artemisia annua flowers (within 24 hours of harvesting) respectively, weigh 200g each, mix, and extract 3 times with 70% ethanol refluxing with 5 times the weight of the materials, combine the extracts, collect and dry, and prepare the extract. Obtain the mixed group V of the herb extract of Herba Uregonii.
分别对藿香、黄蒿花干品原料粉碎,各称取200g,混合,用药材重量5倍70%乙醇回流提取3次,合并提取液,收干,制备浸膏,得到得到青藿提取物混合组VI。Grind the dry raw materials of Huoxiang and Artemisia annua respectively, weigh 200g each, mix them, and extract 3 times with 70% ethanol refluxing which is 5 times the weight of the materials, combine the extracts, dry them up, prepare the extract, and obtain the Herba Herba Herbaii extract Mixed group VI.
实施例2药对青霍挥发油成分的比较The comparison of embodiment 2 medicines to the volatile oil composition of Psyllium
用气相色谱/质谱(GC/MS)法分离检测实施例1中的青藿挥发油混合组A、青藿挥发油混合组B、药对青藿挥发油混合组C和药对青藿挥发油混合组D的挥发油成分,并采用化学计量学解析法(chemometric resolution method,crave)对二维GC-MC数据进行处理。色谱条件为:色谱柱:DB-1(30m×0.2mm);升温程序:起始温度60℃,维持4min。以4℃/min升至220℃,维持2min;载气(He)流速1.0mL/min;进口温度280℃;分流比100:1;进样量10μL。质谱条件为:电子轰击(EI)离子源;电子能量70eV,离子源温度200℃,界面温度250℃。倍增电压:0.80kV,扫描范围m/z35-500;扫描速率:5.0次/s,溶剂延迟2.5min。挥发油中各成分的百分比变化,如表1所示。Gas chromatography/mass spectrometry (GC/MS) method is used to separate and detect the mixed group A of Qinghuo volatile oil, the mixed group B of Qinghuo volatile oil, the mixed group C of the volatile oil of Qinghuo and the mixed group D of the volatile oil of Qinghuo in the embodiment 1. The components of the volatile oil were analyzed, and the two-dimensional GC-MC data were processed by the chemometric resolution method (crave). The chromatographic conditions are: chromatographic column: DB-1 (30m×0.2mm); heating program: the initial temperature is 60° C., and it is maintained for 4 minutes. Rise to 220°C at 4°C/min and maintain for 2min; carrier gas (He) flow rate 1.0mL/min; inlet temperature 280°C; split ratio 100:1; injection volume 10μL. The mass spectrometry conditions are: electron bombardment (EI) ion source; electron energy 70eV, ion source temperature 200°C, interface temperature 250°C. Doubling voltage: 0.80kV, scan range m/z35-500; scan rate: 5.0 times/s, solvent delay 2.5min. The percentage change of each component in the volatile oil is shown in Table 1.
表1药对青藿挥发油的主要成分Table 1 The main components of the volatile oil of Qinghuo
实验结果表明,经过统计青蒿、藿香单味药材的挥发油组合和药对青蒿藿香药对挥发油的12种主要成分差异,发现青蒿-藿香药对挥发油与单味药藿香、青蒿挥发油在质与量上均存在明显差异。青藿药对香挥发油组分主要来自于单味药青蒿,化学组分种类基本不同于2个单味药物的加和,单味药挥发油组分的含量在药对中发生了变化。其中,药对青蒿藿香药对挥发油中消失的成分为(+)-长莰尼酮和α-防风根醇,新增的成分有表蓝桉醇、青蒿酸和丙烯基茴香醚。证明青蒿与藿香两种药物的组合在提取的过程成分及配比关系发生了变化。另外,研究发现,采用青蒿藿香的的鲜品The experimental results show that after statistical analysis of the 12 main components of the volatile oil combination of the single herbs of Artemisia annua and Huoxiang and the difference of the 12 main components of the volatile oil of the herb pair Artemisia annua-Huoxiang There were significant differences in the quality and quantity of the volatile oil of Artemisia annua. The volatile oil components of Pinghuo medicine paired mainly came from the single herb Artemisia annua, the types of chemical components were basically different from the sum of the two single herbal medicines, and the content of the volatile oil components of the single herb medicines changed in the medicine pair. Among them, the missing components in the volatile oil of Artemisia annua and Huoxiang medicine are (+)-long camphenone and α-parsnol, and the newly added components are epicyanool, artemisinic acid and allyl anisole. It proves that the composition and ratio relationship of the combination of Artemisia annua and Huoxiang have changed during the extraction process. In addition, the study found that fresh products using Artemisia annua Huoxiang
实施例2青霍药对组合药物在治疗湿疹方面的应用The application of embodiment 2 Qinghuo medicine to combination medicine in the treatment of eczema
青霍药对组合药物的消炎活性考察Investigation on Anti-inflammatory Activity of Qinghuoyao on Combination Drugs
对小鼠耳廓肿胀的影响研究,取小鼠80只,体质量18~22g.雌雄各半.随机分为对照组、阿司匹林组、青藿提取物混合组I、II组,药对青藿提取物混合组III、IV组,药对青藿提取物混合组V、VI组等8个实验组,每组10只。所述给药组在小鼠左耳廓两侧均匀涂抹实施例1得到的各组青藿提取物,给药量如表3所示,每天2次,连续5d,末次涂药30min后,洗净药膏,用二甲苯以0.1mL/只的量在右耳两侧相同的地方均匀涂抹,左耳作对照,30min后处死。用6mm打孔器取左右耳相同部位耳片,称重,求出肿胀度(左耳质量-右耳质量)。数据用表示,用SPSS15.0统计软件分析,2组间差异用t或t’检验,多组间比较采用F检验,P<O.05为差异具有统计学意义;实验结果见表2所示。For the study of the effect on mouse auricle swelling, 80 mice were taken, with a body weight of 18-22g. Male and female were divided into half and half. They were randomly divided into control group, aspirin group, and Qinghuo extract mixed group I and II groups. There are 8 experimental groups, including the extract mixing group III and IV, and the medicine pair Qinghuo extract mixing group V and VI, with 10 rats in each group. The administration group evenly smears each group of Herba Herba Utarii extract obtained in Example 1 on both sides of the left auricle of the mouse. Clean the ointment, apply xylene at the same place on both sides of the right ear with 0.1mL/cause, the left ear is used as a control, and be killed after 30 minutes. Ear slices from the same parts of the left and right ears were taken with a 6mm punch, weighed, and the degree of swelling (mass of the left ear - mass of the right ear) was calculated. for data Said, analyzed with SPSS15.0 statistical software, the difference between two groups was tested by t or t' test, and the comparison between multiple groups was tested by F test. P<0.05 means that the difference is statistically significant; the experimental results are shown in Table 2.
表2青霍药对组合药物对二甲苯致小鼠耳廓肿胀的影响()The influence of table 2 Qinghuo medicine on the mouse auricle swelling caused by combination drug p-xylene ( )
注:与对照组比较,*P<O.O1。Note: Compared with the control group, * P<O.O1.
青霍药对组合药物的止痒活性考察Investigation on the antipruritic activity of Qinghuoyao on combined drugs
取300-350g豚鼠80只,雌雄各半,随机分为空白对照组、阳性对照组、青藿提取物混合组I、II组,药对青藿提取物混合组III、IV组,药对青藿提取物混合组V、VI组等8个实验组,每组10只。给药各组分别在小鼠右耳耳廓均匀涂抹青霍药对组合药物0.5g·kg-1,阳性对照组在小鼠右耳耳廓均匀涂抹曲咪新乳膏2.0g·kg-1,,空白对照组在小鼠右耳耳廓均匀涂抹空白基质2.0g·kg-1,2次/d,实验前1d,给各组豚鼠右后足背剃毛,并涂药1次。实验当Et,用0号砂纸擦伤动物右后足背剃毛处,以少量渗血为度,面积为1cm2,局部再涂药一次。末次给药后10min。开始在创面处滴以0.O1%磷酸组织胺0.05mL/只,每次间隔时间为3min,直至出现豚鼠回头舔右后足,以开始出现豚鼠回头舔右后足时所给予的磷酸组织胺总量最为致痒阈。记录并比较各组致痒闽,进行组间t检验.结果见表7。从表3可见,药对青藿提取物混合组III、IV组与空白对照组比较,差异有统计学意义(P<0.05或P<0.01)。说明实施例1得到的青霍药对组合药物可显著提高磷酸组胺对豚鼠的致痒阈,且随剂量增大效果更明显。Get 80 guinea pigs of 300-350g, half male and half male, and randomly divided into blank control group, positive control group, mixed group I and II of Qinghuo extract, mixed group III and IV of medicine-paired Qinghuo extract, and group III and IV of medicine-paired Qinghuo extract. There were 8 experimental groups including Huohu extract mixed group V and VI, with 10 rats in each group. In each administration group, 0.5g·kg -1 of the combined drug of Cincinnamon was evenly applied to the right auricle of the mice, and in the positive control group, 2.0g·kg -1 of trimidesin cream was evenly applied to the right auricle of the mice. ,, the blank control group evenly smeared 2.0g·kg -1 of the blank matrix on the right auricle of the mice, twice a day, 1 day before the experiment, shaved the dorsum of the right hind foot of the guinea pigs in each group, and applied the medicine once. When the experiment was Et, use No. 0 sandpaper to scrape the shaved part of the right hind foot of the animal, with a small amount of blood oozing, and the area is 1cm 2 , and then apply the medicine once again. 10 minutes after the last dose. Start to drop 0.01% histamine phosphate 0.05mL/on the wound, with an interval of 3 minutes each time, until the guinea pig turns back to lick its right hind foot, so that the phosphate histamine given when the guinea pig turns back to lick its right hind foot begins to appear The total amount is the most itchy threshold. Record and compare the itching of each group, and perform the t test between groups. The results are shown in Table 7. As can be seen from Table 3, compared with the blank control group, there is a statistically significant difference (P<0.05 or P<0.01). Illustrate that the combination of cyanosides obtained in Example 1 can significantly improve the itching threshold of histamine phosphate on guinea pigs, and the effect is more obvious as the dose increases.
表3青霍药对组合药物对磷酸组胺致足瘙痒的影响(n=10)Table 3 The influence of Chinese cholera on combined drugs on foot itching caused by histamine phosphate ( n=10)
注:与空白组比较,*P<O.05,#P<O.O1。Note: Compared with the blank group, * P<O.05, # P<O.O1.
取300-350g豚鼠60只,用8%硫化钠溶液将豚鼠背部脱毛,面积为4cm×6cm,每鼠背部脱毛区涂抹1%DNCB丙酮溶液0.02mL致敏1次,3d后二次致敏。第十四天再以1%DNCB丙酮溶液0.02mL激发1次,豚鼠背部涂药部位出现过敏性接触性皮炎症状。将上述豚鼠随机分为5组,每组10只,雌雄各半,分别为青藿提取物混合组I、II组,药对青藿提取物混合组IIIIIV组,药对青藿提取物混合组V、VI组,阳性对照组及空白对照组。青霍药对组合药物组给药实施例2得到市售产品1.0g·kg-1;青藿提取物混合组I、II组,药对青藿提取物混合组III、IV组,药对青藿提取物混合组V、VI组分别在病损部位均匀涂抹实施例1得到的组合药物0.5g·kg-1,阳性对照组在病损部位均匀涂抹曲咪新乳膏4.0g·kg-1,空白对照组在病损部位均匀涂抹空白基质4.0g·kg-1,2次/d,连续7d。第8d后处死豚鼠,用打孔器(直径15mm)取下同一部位的病损皮肤,电子天平称质量,同时用游标卡尺测皮肤厚度。结果见表4。与空白对照组比较,青藿提取物混合组I、II组,药对青藿提取物混合组III、IV组,药对青藿提取物混合组V、VI组皮肤重量、皮肤厚度均有统计学差异(P<0.O1),说明青霍药对组合药物和阳性对照组各组对DNCB诱发豚鼠过敏性接触性皮炎有一定的治疗和抑制作用。Take 60 guinea pigs of 300-350 g, depilate the back of the guinea pigs with 8% sodium sulfide solution, with an area of 4cm×6cm, apply 0.02mL of 1% DNCB acetone solution to the depilated area of each mouse for one time, and then sensitize for the second time after 3 days. On the fourteenth day, it was challenged once again with 0.02 mL of 1% DNCB acetone solution, and allergic contact dermatitis symptoms appeared on the back of guinea pigs where the drug was applied. The above-mentioned guinea pigs were randomly divided into 5 groups, 10 in each group, half male and half male, respectively, the mixed group I and II of Qinghuo extract, the mixed group IIIIIIV of the extract of Qinghuo, and the mixed group of extract of Qinghuo. V, VI groups, positive control group and blank control group. The administration example 2 of Qinghuo medicine to the combination drug group obtains the commercially available product 1.0g kg −1 ; the mixed group I and II of Qinghuo extract, the mixed group III and IV of the medicine paired with Qinghuo extract, and the mixed group III and IV of the medicine paired with Qinghuo. The Huohu extract mixed group V and VI were evenly applied to the lesion site with 0.5g·kg -1 of the combined drug obtained in Example 1, and the positive control group was evenly applied to the lesion site with 4.0g·kg -1 Trimetin cream In the blank control group, 4.0 g·kg -1 of blank matrix was evenly applied to the lesion, twice a day for 7 consecutive days. After the 8th day, the guinea pigs were executed, and the lesioned skin of the same part was removed with a punch (15 mm in diameter), weighed with an electronic balance, and the skin thickness was measured with a vernier caliper. The results are shown in Table 4. Compared with the blank control group, the skin weight and skin thickness of Qinghuo extract mixed group I and II, medicine pair Qinghuo extract mixed group III and IV, and medicine pair Qinghuo extract group V and VI were statistically The difference (P<0.01) shows that Qinghuo medicine has a certain therapeutic and inhibitory effect on DNCB-induced guinea pig allergic contact dermatitis to combination medicine and each group of positive control group.
表4青霍药对组合药物对过敏性皮炎的影响(n=10)Table 4 Qinghuo medicine on the impact of combination drugs on atopic dermatitis ( n=10)
注:与空白组比较,*P<O.01。Note: Compared with blank group, * P<O.01.
湿疹是由各种内外因素引起的一种常见皮肤病,在急性阶段以丘疹为主,慢性阶段以表皮肥厚和苔癣样变为主的瘙痒性皮肤病。西医认为这类疾病多与过敏反应有关,并常伴有细菌感染。全身治疗常采用抗过敏疗法,而局部治疗常采用激素加抗菌素进行治疗,但由于激素的毒副作用,使得该病成为难治的疾病,给患者的身心健康带来了极大的危害。本实施例中,通过对比实施例1中得到的各组提取物活性;发现在消肿、止痒和对过敏性皮炎等方面,药对青藿提取物混合组III、IV组的活性优于药对青藿提取物混合组V、VI组和青藿提取物混合组I、II组。Eczema is a common skin disease caused by various internal and external factors. It is mainly papules in the acute stage, and a pruritic skin disease that is dominated by epidermal hypertrophy and lichenification in the chronic stage. Western medicine believes that these diseases are mostly related to allergic reactions, and are often accompanied by bacterial infections. Systemic treatment often uses anti-allergic therapy, while local treatment often uses hormone plus antibiotics for treatment. However, due to the toxic and side effects of hormones, the disease has become an intractable disease, which has brought great harm to the patient's physical and mental health. In the present embodiment, by comparing the activity of each group of extracts obtained in Example 1; it is found that in terms of detumescence, antipruritic and atopic dermatitis, the activity of the medicine to the mixed group III and IV of Qinghuo extract is better than that of group III and IV. Herbal extract mixed group V and VI and extract mixed group I and II of Qinghuo.
实施例3青藿提取物混合组在止咳化痰方面的应用Example 3 Application of the mixed group of Qinghuo extract in relieving cough and reducing phlegm
根据现有技术研究证明,青蒿和藿香的挥发油都具有止咳平喘的活性。将实施例1中制备的到青蒿挥发油和藿香挥发油分别作为青蒿挥发油组和藿香挥发油组;According to prior art studies, it has been proved that the volatile oils of Artemisia annua and Huoxiang all have the activity of relieving cough and relieving asthma. The Artemisia annua volatile oil and Huoxiang volatile oil prepared in embodiment 1 are respectively used as Artemisia annua volatile oil group and Huoxiang volatile oil group;
取18~20g雌性小鼠80只,随机分为8组,每组10只,分别为空白对照组(等量蒸馏水)、青蒿挥发油组、藿香挥发油组、青藿提取物混合组II组、药对青藿提取物混合组IV组、青藿提取物混合组VI组及阳性对照组(氢溴酸右美沙芬片)。给药动物按体重(5g原药材/kg)灌胃,给药次数1次/d,连续给药14d。实验前各组动物禁食不禁水10h,末次给药,前4组按上述方法灌胃,阳性对照组以0.05g/kg的剂量给予相对应的药液灌胃1次,给药后30min,各组小鼠分别放入自制诱咳仪(氨气浓度为15%),20s后取出,观察记录小鼠的咳嗽潜伏期和3min内咳嗽次数。t检验比较各给药组与空白对照组之间咳嗽潜伏期和咳嗽次数的差异显著性。具体结果见表5所示。Take 80 female mice weighing 18-20 g, and randomly divide them into 8 groups, 10 in each group, which are blank control group (equal volume of distilled water), Artemisia annua volatile oil group, Huoxiang volatile oil group, and Qinghuo extract mixed group II , medicine pair Qinghuo extract mixed group IV, Qinghu extract mixed group VI and positive control group (dextromethorphan hydrobromide tablets). Animals were administered by intragastric administration according to body weight (5g raw medicinal material/kg), and the administration frequency was 1 time/d, and the administration was continued for 14 days. Before the experiment, the animals in each group were fasted for 10 hours, and the last administration was given. The first 4 groups were gavaged by the above-mentioned method, and the positive control group was given the corresponding medicinal solution by gavage once at a dose of 0.05 g/kg, and 30 minutes after the administration. The mice in each group were put into a self-made cough-inducing instrument (the concentration of ammonia gas was 15%), and were taken out after 20 seconds. The cough latency and the number of coughs within 3 minutes of the mice were observed and recorded. The t-test was used to compare the significant differences in cough latency and cough times between each administration group and the blank control group. The specific results are shown in Table 5.
表5药对青藿提取物混合组对小鼠止咳作用(n=10)The medicine of table 5 is to the antitussive effect of the mixed group of Qinghuo extract on mice ( n=10)
注:与空白组比较,*P﹥0.05,**P﹥0.01。Note: Compared with the blank group, *P﹥0.05, ** P﹥0.01.
取18~20g雄性小鼠80只,随机分为8组,每组10只,分别为空白对照组(等量蒸馏水)、青蒿挥发油组、藿香挥发油组、青藿提取物混合组II组、药对青藿提取物混合组IV组、青藿提取物混合组VI组以及阳性对照组(氯化铵组)。给药动物按体重(5g原药材/kg)灌胃,给药次数1次/d,连续给药14d。实验前各组动物禁食不禁水10h,末次给药前4组按上述方法灌胃,阳性对照组以1g/kg的剂量给予相对应的药液灌胃,给药后30min,各组小鼠分别腹腔注射5%酚红溶液按体重(0.1mL/10g)注射酚红后30min,用乙醚处死动物,小心剥离气管周围组织,剪下白甲状软骨下至气管分叉处的一段气管,立刻用配制好的5%碳酸氢钠溶液0.5mL冲洗,连续3次,洗出液合并,置于722型分光光度计,于546nm波长处测定OD值。t检验比较各给药组与空白对照组之间吸光度的差异显著性。具体结果见表6所示。研究证明,药对青藿提取物混合组VI组在止咳化痰方面不具有活性,与青蒿挥发油组、藿香挥发油组和青藿提取物混合组II组在止咳方面具有活性,但是不具有化痰的活性,而不仅具有止咳的活性,同时还具有化痰的良好活性。Take 80 male mice of 18-20 g, and randomly divide them into 8 groups, 10 in each group, which are blank control group (equal volume of distilled water), Artemisia annua volatile oil group, Huoxiang volatile oil group, and Qinghuo extract mixed group II , Medicinal herb extract mixed group IV, group VI mixed with extract of Qinghuo and positive control group (ammonium chloride group). Animals were administered by intragastric administration according to body weight (5g raw medicinal material/kg), and the administration frequency was 1 time/d, and the administration was continued for 14 days. Before the experiment, the animals in each group were fasted for 10 hours, and before the last administration, the 4 groups were intragastrically administered according to the above method, and the positive control group was intragastrically administered with the corresponding medicinal solution at a dose of 1 g/kg. Inject 5% phenol red solution into the intraperitoneal cavity according to body weight (0.1mL/10g) 30 minutes after injecting phenol red, kill the animals with ether, carefully peel off the tissues around the trachea, cut off the white thyroid cartilage down to a section of the trachea at the bifurcation of the trachea, and immediately use The prepared 5% sodium bicarbonate solution was rinsed with 0.5mL for 3 consecutive times, the eluates were combined, placed in a 722-type spectrophotometer, and the OD value was measured at a wavelength of 546nm. The t test was used to compare the significance of the difference in absorbance between each treatment group and the blank control group. The specific results are shown in Table 6. The study proved that the mixed group VI of herb extracts of Qinghuo has no activity in relieving cough and reducing phlegm, and the group II mixed with the volatile oil group of Artemisia annua, Huoxiang volatile oil and Qinghuo extract has activity in relieving cough, but not The activity of reducing phlegm, not only has the activity of antitussive, but also has the good activity of reducing phlegm.
表6药对青藿提取物混合组的化痰作用(n=10)The expectorant effect of table 6 medicines to the mixed group of Qinghuo extract ( n=10)
注:与空白组比较,*P﹥0.05,**P﹥0.01。Note: Compared with the blank group, * P﹥0.05, ** P﹥0.01.
Claims (6)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013104513929A CN103463185A (en) | 2013-09-29 | 2013-09-29 | Matched artemisia apiacea and agastache rugosaus combination medicine, preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013104513929A CN103463185A (en) | 2013-09-29 | 2013-09-29 | Matched artemisia apiacea and agastache rugosaus combination medicine, preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103463185A true CN103463185A (en) | 2013-12-25 |
Family
ID=49788377
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013104513929A Pending CN103463185A (en) | 2013-09-29 | 2013-09-29 | Matched artemisia apiacea and agastache rugosaus combination medicine, preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103463185A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106974995A (en) * | 2017-04-26 | 2017-07-25 | 重庆市中药研究院 | One kind is used for Hirudo japonica externally applied compound medicinal, preparation and its application |
| CN113662978A (en) * | 2021-09-30 | 2021-11-19 | 梵申兰科技(上海)有限公司 | Artemisia apiacea essential oil and white tea essential oil for treating eczema and composition thereof |
-
2013
- 2013-09-29 CN CN2013104513929A patent/CN103463185A/en active Pending
Non-Patent Citations (2)
| Title |
|---|
| 熊运海等: "《药对青蒿-藿香挥发油成分的气相色谱-质谱和化学计量学分析》", 《药学学报》 * |
| 熊运海等: "《藿香与青蒿挥发油及其复合物抑菌活性及化学成分研究》", 《食品科学》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106974995A (en) * | 2017-04-26 | 2017-07-25 | 重庆市中药研究院 | One kind is used for Hirudo japonica externally applied compound medicinal, preparation and its application |
| CN113662978A (en) * | 2021-09-30 | 2021-11-19 | 梵申兰科技(上海)有限公司 | Artemisia apiacea essential oil and white tea essential oil for treating eczema and composition thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bedi et al. | Herbal therapy in dermatology | |
| Cassileth et al. | Herb-drug interactions in oncology | |
| Nomicos | Myrrh: medical marvel or myth of the magi? | |
| Déciga-Campos et al. | Synergistic herb‐herb interaction of the antinociceptive and anti‐inflammatory effects of Syzygium aromaticum and Rosmarinus officinalis combination | |
| US20180055903A1 (en) | Homeopathic composition comprising hypericum perforatum extract and essential oils for the treatment of neuropathic pain | |
| Fugh-Berman | The 5-minute herb and dietary supplement consult | |
| CN112870318A (en) | A Chinese medicinal composition with analgesic and antiviral effects, and its administration method and preparation method | |
| WO2021205196A4 (en) | Compositions and prevention and intervention methods for covid-19 with divine ayats' fitra30 covid-19 protocol | |
| Pal et al. | Plant leads for mitigation of oral submucous fibrosis: Current scenario and future prospect | |
| Musthaba et al. | Patented herbal formulations and their therapeutic applications | |
| Solanki | Treatment of skin diseases through medicinal plants in different regions of the world | |
| JP2019515870A (en) | Antiviral compositions and methods | |
| CN100353996C (en) | Medicine composition for treating soft tissue damage and osteoarthropathy and its prepn process | |
| US20220105107A1 (en) | Bioidentical progesterone cream infused with nanoemulsified cbd | |
| EP3833371B1 (en) | Formulations containing lipophilic extracts of spicy edible plants useful in controlling pain and inflammation | |
| CN100350966C (en) | Chinese medicinal preparation for treating gynecopathy inflammation and its preparing process | |
| CN101234140A (en) | A kind of pharmaceutical composition for treating eczema and its preparation method and application | |
| Hairunisa et al. | Pharmacological and anticancer potential of black ginger (Kaempferia parviflora)-Review Article | |
| Díaz-Murillo et al. | Natural health products for psoriasis management | |
| CN102727542A (en) | Ointment with function of relieving swelling and pain | |
| CN103285087A (en) | Application of Humunus Lupulus L's effective part in preparation of drugs for preventing and improving anxiety and its clinical symptoms | |
| US20260102453A1 (en) | Neem tree leaves extract | |
| Gholami et al. | Inhibitory effect of cinnamon extract on gelophen induced nephrotoxicity in adalt rats | |
| Rani et al. | A Narrative Review on the Anti-inflammatory Potential of Mamsyadi Yoga: Bridging Ayurveda and Modern Pharmacology | |
| RU2471495C1 (en) | Hemorheologic phytodrug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20131225 |










